Overview

• Ophthalmic pharma firm's preliminary Q4 net sales rose 36%, beating analyst expectations

• Company ended Q4 with $283 mln in cash and no debt

Outlook

• Glaukos reaffirms 2026 revenue guidance of $600 mln to $620 mln

• Company expects sustained growth momentum due to novel technology pipeline

Result Drivers

• IDOSE TR SALES - iDose TR contributed $45 mln to U.S. Glaucoma net sales in Q4, highlighting its strong market performance

• CORNEAL HEALTH SALES - Corneal Health net sales reached $24 mln in Q4, contributing to overall sales growth

• INTERNATIONAL GROWTH - International Glaucoma net sales were $33 mln in Q4, supporting global sales increase

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Glaukos Corp is $127.50, about 15% above its January 12 closing price of $110.91

Press Release: ID:nBwb0Y99a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)